This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.90% per year. These returns cover a period from January 1, 1988 through December 1, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechnology: Archive
ADMA Biologics Reports Preliminary 2025 Results, Ups 2026 Outlook
by Zacks Equity Research
ADMA expects 2025 revenues of approximately $510-$511 million, raising 2026 guidance on strong Asceniv demand and margin expansion.
FOLDPositive Net Change ADMANegative Net Change KRYSPositive Net Change
biotechnology biotechs medical pharmaceuticals
Novo Nordisk Soars 19% in a Month: How Should You Play the Stock?
by Ahan Chakraborty
NVO jumps nearly 19% in a month primarily on the FDA approval and launch of oral Wegovy, the first GLP-1 pill for obesity and cardiovascular risk reduction.
NVONegative Net Change LLYNegative Net Change VKTXNegative Net Change
biotechnology biotechs medical pharmaceuticals
Plains All American Pipeline (PAA) Now Trades Above Golden Cross: Time to Buy?
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
PAAPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
KRYS Reports Preliminary Results for 2025, Outlines 2026 Objectives
by Zacks Equity Research
On a preliminary unaudited basis, Krystal Biotech expects revenues of $388-$389M in 2025. The company ended the year with $955M cash, and outlined 2026 plans as its pipeline advances.
FOLDPositive Net Change CRMDNegative Net Change KRYSPositive Net Change
biotechnology biotechs gene-therapy medical pharmaceuticals
PCRX Stock Down 10% as Preliminary Q4 Revenues Miss Estimates
by Zacks Equity Research
Pacira BioSciences stock slides nearly 10% after preliminary Q4 revenues of $196.9 million miss estimates, despite Exparel sales topping forecasts.
FOLDPositive Net Change PCRXNegative Net Change CRMDNegative Net Change INDVNegative Net Change
biotechnology biotechs medical pharmaceuticals
TEVA Signs Deal With RPRX to Accelerate Development of Vitiligo Drug
by Zacks Equity Research
Teva strikes a $500M funding deal with Royalty Pharma for the speedy development of its vitiligo candidate, TEV-'408, while keeping global commercial control.
TEVANegative Net Change RPRXPositive Net Change CRMDNegative Net Change INDVNegative Net Change
biotechnology biotechs medical pharmaceuticals
Exelixis Posts Preliminary '25 Results, Issues '26 Outlook
by Zacks Equity Research
EXEL posts approximately $2.32B in 2025 revenues and guides $2.525 -$2.625B for 2026 as Cabometyx grows and a zanzalintinib NDA advances.
RHHBYPositive Net Change EXELPositive Net Change FOLDPositive Net Change CRMDNegative Net Change
biotechnology biotechs medical pharmaceuticals
J&J Strikes Drug Pricing Deal With Trump, Gets Tariff Reprieve
by Zacks Equity Research
JNJ cuts U.S. drug prices under a Trump deal, gains a tariff reprieve, and accelerates a $55 billion push to expand domestic manufacturing.
AZNPositive Net Change JNJPositive Net Change LLYNegative Net Change ABBVPositive Net Change
biotechnology biotechs medical pharmaceuticals
VKTX Completes Enrollment in Phase I Maintenance Study of Obesity Drug
by Zacks Equity Research
Viking Therapeutics completes enrollment in a phase I maintenance study of VK2735, testing flexible oral and injectable dosing after initial weight loss in obese adults.
NVONegative Net Change LLYNegative Net Change VKTXNegative Net Change GPCRPositive Net Change
biotechnology biotechs medical pharmaceuticals
Bayer Accelerates Growth With siRNA, AI Deals and Pipeline Progress
by Zacks Equity Research
Bayer AG enters into collaborations to develop a heart-targeted siRNA therapy and AI technology, expanding its push into next-gen genetic medicines.
JNJPositive Net Change BAYRYNegative Net Change FOLDPositive Net Change CRMDNegative Net Change
biotechnology biotechs medical pharmaceuticals
BMY Rallies 17.3% in Six Months: Buy, Sell or Hold the Stock?
by Ekta Bagri
BMY shares have surged in the past six months, driven by Opdivo, Reblozyl and a guidance raise, as growth drugs offset mounting generic pressure
BMYPositive Net Change PFENegative Net Change MRKNegative Net Change BNTXPositive Net Change
biotechnology biotechs medical pharmaceuticals
New Strong Buy Stocks for January 9th
by Zacks Equity Research
BDTX, LUMN, ADEA, ACRE and TACT have been added to the Zacks Rank #1 (Strong Buy) List on January 9th, 2026.
ACRENegative Net Change TACTNegative Net Change BDTXPositive Net Change LUMNPositive Net Change ADEANegative Net Change
biotechnology reit
Should You Buy Electrolux AB (ELUXY) After Golden Cross?
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
ELUXYPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
KRYS Stock Surges 57% in a Year: More Upside Potential in 2026?
by Zacks Equity Research
Shares of Krystal Biotech soar 57% in a year as strong Vyjuvek uptake and steady pipeline progress continue to push the stock higher.
FOLDPositive Net Change CRMDNegative Net Change KRYSPositive Net Change
biotechnology biotechs gene-therapy medical pharmaceuticals
Is LLY's Ventyx Deal Another Attempt at Diversification Beyond GLP-1?
by Ahan Chakraborty
Eli Lilly ramps up M&A activity, adding Ventyx and other assets to diversify beyond obesity as competition in the GLP-1 space intensifies.
PFENegative Net Change NVONegative Net Change LLYNegative Net Change VTYXPositive Net Change
biotechnology biotechs medical pharmaceuticals
EXEL Collaborates With Natera for Late-Stage Colorectal Cancer Study
by Zacks Equity Research
Exelixis teamed with Natera on the phase III STELLAR-316 study testing zanzalintinib in resected stage II/III colorectal cancer. Stock gains.
RHHBYPositive Net Change EXELPositive Net Change FOLDPositive Net Change CRMDNegative Net Change NTRAPositive Net Change
biotechnology biotechs medical pharmaceuticals
Denali Therapeutics Unveils Portfolio Goals for 2026, Stock Up
by Zacks Equity Research
DNLI maps 2026 goals as it awaits FDA action on tividenofusp alfa, targeting first commercial validation amid multiple late-stage readouts.
SNYNegative Net Change BIIBNegative Net Change DNLIPositive Net Change TAKNegative Net Change
biotechnology biotechs medical pharmaceuticals
MARKER THERAPEUTICS, INC. (MRKR) Now Trades Above Golden Cross: Time to Buy?
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
MRKRNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
OTLK Stock Crashes 67% in a Week: Here's What You Need to Know
by Zacks Equity Research
Outlook Therapeutics stock plunges 67% in a week after the FDA issues a third CRL rejecting its ONS-5010 BLA for wet AMD, again seeking confirmatory data.
FOLDPositive Net Change CRMDNegative Net Change OTLKNegative Net Change INDVNegative Net Change
biotechnology biotechs medical pharmaceuticals
INCY's Phase III Monjuvi Study Meets Key Goals in First-Line Lymphoma
by Zacks Equity Research
Incyte's phase III study of Monjuvi combo for first-line DLBCL treatment met primary and key secondary goals, paving the way for a 2026 FDA filing.
BMYPositive Net Change INCYNegative Net Change ANIPNegative Net Change CRMDNegative Net Change
biotechnology biotechs medical pharmaceuticals
Can the US Launch of NVO's Wegovy Pill Reignite Momentum in 2026?
by Ahan Chakraborty
Novo Nordisk shares jump after the U.S. launch of its FDA-approved Wegovy pill, giving the first oral GLP-1 weight-loss drug a chance to revive 2026 momentum.
NVONegative Net Change LLYNegative Net Change VKTXNegative Net Change
biotechnology biotechs medical pharmaceuticals
Three Genomics Stocks Worth Tracking This Year
by Ekta Bagri
Genomics advances are reshaping drug discovery, with Pacific Biosciences of California emerging as a key player in next-gen sequencing.
ILMNPositive Net Change BEAMPositive Net Change PACBPositive Net Change WVEPositive Net Change CRSPPositive Net Change SANAPositive Net Change
biotechnology biotechs cell-therapy gene-therapy genetics genomics medical pharmaceuticals thematic
KYMR Skyrockets 82.4% in a Year: More Upside Potential in 2026?
by Zacks Equity Research
KYMR rallied 82% in a year as KT-621 delivered strong phase Ib BroADen data and earned FDA Fast Track for atopic dermatitis.
REGNNegative Net Change SNYNegative Net Change GILDNegative Net Change KYMRPositive Net Change
biotechnology biotechs medical pharmaceuticals
Will NVO's Wegovy Pill Approval for Obesity be a Game Changer in 2026?
by Ahan Chakraborty
Novo Nordisk's FDA-approved Wegovy pill marks the first oral GLP-1 weight loss therapy, aiming to revive momentum and reshape competition in 2026.
NVONegative Net Change LLYNegative Net Change VKTXNegative Net Change
biotechnology biotechs medical pharmaceuticals
Will ANIP's Rare Disease Franchise Maintain Momentum in 2026?
by Ekta Bagri
ANIP's rare disease push, led by Cortrophin Gel, drove 70% sales growth in the first nine months of 2025, lifting revenue outlook.
REGNNegative Net Change ABBVPositive Net Change ANIPNegative Net Change
biotechnology biotechs medical pharmaceuticals